IBRUTINIB --MANTLE CELL LYMPHOMA (MCL)
Ø On November 13,
2013, the U. S. Food and Drug Administration granted accelerated
approval to Ibrutinib for RX OF mantle cell lymphoma (MCL) who have received
at least
one prior therapy.
Ø Ibrutinib
is a FIRST potent covalent kinase
inhibitor that targets BTK. Bruton's
tyrosine kinase, target for therapy of B cell diseases
No comments:
Post a Comment